D8809

应用筛选条件

关键词:'D8809'

显示 1-30 共 74 条结果关于 "D8809" 范围论文

Liposomes modified with p-aminophenyl-α-D-mannopyranoside: a promising delivery system in targeting the brain.

Haisheng Peng et al.

Therapeutic delivery, 4(12), 1475-1477 (2013-12-07)

Orientia tsutsugamushi Strain Ikeda Ankyrin Repeat-Containing Proteins Recruit SCF1 Ubiquitin Ligase Machinery via Poxvirus-Like F-Box Motifs.

Andrea R Beyer et al.

Journal of bacteriology, 197(19), 3097-3109 (2015-07-15)

A rising theme among intracellular microbes is the delivery of ankyrin repeat-containing effectors (Anks) that interact with target proteins to co-opt host cell functions. Orientia tsutsugamushi, an obligate intracellular bacterium and the etiologic agent of scrub typhus, encodes one of

Post-chemotherapeutic resolution of acute myeloid leukaemia-induced gingival enlargement: a case report.

S Singh-Rambiritch et al.

SADJ : journal of the South African Dental Association = tydskrif van die Suid-Afrikaanse Tandheelkundige Vereniging, 67(7), 344-347 (2013-08-21)

Leukaemia is a neoplastic dsorder characterized by an excessive proliferation of immature white blood cells and their precursors. Patients with this potentially fatal condition may often first present with gingival enlargement. Early diagnosis of the underlying condition and prompt referral

Oxidized porous silicon particles covalently grafted with daunorubicin as a sustained intraocular drug delivery system.

Jay Chhablani et al.

Investigative ophthalmology & visual science, 54(2), 1268-1279 (2013-01-17)

To test the feasibility of covalent loading of daunorubicin into oxidized porous silicon (OPS) and to evaluate the ocular properties of sustained delivery of daunorubicin in this system. Porous silicon was heat oxidized and chemically functionalized so that the functional

Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse.

Sylvain Pilorge et al.

American journal of hematology, 89(4), 399-403 (2014-01-01)

Gemtuzumab ozogamicin (fGO), a humanized anti-CD33 monoclonal antibody linked to calicheamicin in combination with intensive chemotherapy gives high response rates in adult acute myeloid leukemia (AML) patients in relapse. However, reduced intensity chemotherapy in combination with fractionated GO has not

Idarubicin is superior to daunorubicin in remission induction of de novo acute myeloid leukemia patients with high MDR1 expression.

Pengcheng Shi et al.

Pharmacogenomics, 14(1), 17-23 (2012-12-21)

To investigate whether idarubicin in a cytarabine-based induction regimen was superior to daunorubicin in de novo acute myeloid leukemia patients expressing high MDR1. The clinicopathological data were analyzed in 125 patients receiving daunorubicin or idarubicin with cytarabine for remission induction.

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia.

Stephen H Petersdorf et al.

Blood, 121(24), 4854-4860 (2013-04-18)

This randomized phase 3 clinical trial evaluated the potential benefit of the addition of gemtuzumab ozogamicin (GO) to standard induction and postconsolidation therapy in patients with acute myeloid leukemia. Patients were randomly assigned to receive daunorubicin (45 mg/m(2) per day

Binding of daunomycin to DNA and the inhibition of RNA and DNA synthesis.

N S Mizuno et al.

Cancer research, 35(6), 1542-1546 (1975-06-01)

With synchronized tissue culture cells (L929), daunomycin had the greatest inhibitory effect on cell growth when the drug was administered during the later stages of cell division (late S, G2, and M). The level of binding of daunomycin to DNA

2D- and 3D-QSAR studies of a series of benzopyranes and benzopyrano[3,4b][1,4]-oxazines as inhibitors of the multidrug transporter P-glycoprotein.

Ishrat Jabeen et al.

Journal of computer-aided molecular design, 27(2), 161-171 (2013-02-13)

The ATP-binding cassette efflux transporter P-glycoprotein (P-gp) is notorious for contributing to multidrug resistance in antitumor therapy. Due to its expression in many blood-organ barriers, it also influences the pharmacokinetics of drugs and drug candidates and is involved in drug/drug-

Binding of the plant alkaloid aristololactam-β-d-glucoside and antitumor antibiotic daunomycin to single stranded polyribonucleotides.

Abhi Das et al.

Biochimica et biophysica acta, 1830(10), 4708-4718 (2013-06-19)

Interaction of the plant alkaloid aristololactam-β-d-glucoside and the antitumor drug daunomycin with single stranded RNAs poly(G), poly(I), poly(C) and poly(U) has been investigated. Biophysical techniques of absorption, fluorescence, competition dialysis, circular dichroism, and microcalorimetry have been used. Absorption and fluorescence

Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.

Jorge E Cortes et al.

Cancer, 121(2), 234-242 (2014-09-17)

CPX-351 is a liposome-encapsulated fixed-molar-ratio formulation of cytarabine and daunorubicin that exploits molar ratio-dependent drug-drug synergy to enhance antileukemic efficacy. This phase II study randomized 125 patients 2:1 to CPX-351 or investigators' choice of first salvage chemotherapy. Patients with acute

Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.

Enrico De Astis et al.

Annals of hematology, 93(12), 2011-2018 (2014-07-06)

Therapeutic options for patients with relapsed or refractory acute leukemia are still undefined and often unsatisfactory. We report the outcome of 79 patients with relapsed-refractory acute leukemia treated with fludarabine, cytarabine, and liposomal daunorubicin (FLAD regimen) followed by hematopoietic stem

EVI1 inhibits apoptosis induced by antileukemic drugs via upregulation of CDKN1A/p21/WAF in human myeloid cells.

Anna Rommer et al.

PloS one, 8(2), e56308-e56308 (2013-03-05)

Overexpression of ecotropic viral integration site 1 (EVI1) is associated with aggressive disease in acute myeloid leukemia (AML). Despite of its clinical importance, little is known about the mechanism through which EVI1 confers resistance to antileukemic drugs. Here, we show

The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents.

Cedric Dos Santos et al.

Blood, 122(11), 1900-1913 (2013-07-31)

The SRC family kinases (SFKs) and the receptor tyrosine kinase c-Kit are activated in human acute myeloid leukemia (AML) cells. We show here that the SFKs LYN, HCK, or FGR are overexpressed and activated in AML progenitor cells. Treatment with

In vitro flow cytometry method to quantitatively assess inhibitors of P-glycoprotein.

E J Wang et al.

Drug metabolism and disposition: the biological fate of chemicals, 28(5), 522-528 (2000-04-20)

P-glycoprotein (Pgp)-mediated drug efflux is a major factor contributing to the variance of absorption and distribution of many drugs. A simple and reliable in vitro method to identify inhibitors of Pgp helps to prevent the potential of drug interactions. Using

Ewing sarcoma arising after treatment of diffuse large B-cell lymphoma.

Nobuhiro Hiramoto et al.

Japanese journal of clinical oncology, 43(4), 417-421 (2013-03-12)

We report the case of a patient in whom the diagnosis of Ewing sarcoma arising from a soft tissue was made after successful treatment of diffuse large B-cell lymphoma. A 65-year-old woman presented with a rapidly growing mass in her

In vitro induction of apoptosis and necrosis by new derivatives of daunorubicin.

Marta Stojak et al.

Anticancer research, 33(10), 4439-4443 (2013-10-15)

The comparative effects of daunorubicin, and its new formamidine derivatives containing either a morpholine moiety (DAUFmor) or a hexamethyleneimine moiety (DAUFhex) in the amidine group, on induction of programmed cell death were determined. The experiments were performed on human acute

ERK Activity in Immature Leukemic Cells Drives Clonal Selection during Induction Therapy for Acute Myeloid Leukemia.

Michal Hayun et al.

Scientific reports, 10(1), 8349-8349 (2020-05-21)

Selection of resistant clones following intensive chemotherapy is a common obstacle for cure in many cancers, particularly in acute myeloid leukemia (AML). In AML, clone-specific sensitivity to chemotherapy varies even within the same patient. Multiple mutations and genetic aberrations are

Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3.

Jakub Hofman et al.

Toxicology and applied pharmacology, 278(3), 238-248 (2014-05-17)

Pharmacokinetic drug resistance is a serious obstacle that emerges during cancer chemotherapy. In this study, we investigated the possible role of aldo-keto reductase 1C3 (AKR1C3) in the resistance of cancer cells to anthracyclines. First, the reducing activity of AKR1C3 toward

Impact on survival and toxicity by duration of weight extremes during treatment for pediatric acute lymphoblastic leukemia: A report from the Children's Oncology Group.

Etan Orgel et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32(13), 1331-1337 (2014-04-02)

Previous studies regarding the influence of weight on event-free survival (EFS) and treatment-related toxicity (TRT) in childhood acute lymphoblastic leukemia (ALL) considered only weight at diagnosis. Inasmuch as weight varies substantially over treatment, we hypothesized its impact on EFS is

Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group.

Gertjan J L Kaspers et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(5), 599-607 (2013-01-16)

In pediatric relapsed acute myeloid leukemia (AML), optimal reinduction therapy is unknown. Studies suggest that liposomal daunorubicin (DNX; DaunoXome; Galen, Craigavon, United Kingdom) is effective and less cardiotoxic, which is important in this setting. These considerations led to a randomized

Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5'-nucleotidase.

Ingrid Jakobsen Falk et al.

American journal of hematology, 88(12), 1001-1006 (2013-07-23)

De novo acute myeloid leukemia with normal karyotype (NK-AML) comprises a large group of patients with no common cytogenetic alterations and with a large variation in treatment response. Single-nucleotide polymorphisms (SNPs) in genes related to the metabolism of the nucleoside

Epigenetic regulation of tissue factor inducibility in endothelial cell senescence.

David J Kurz et al.

Mechanisms of ageing and development, 140, 1-9 (2014-07-20)

Cellular senescence, a programmed state induced by multiple deleterious triggers, is characterised by permanent cell-cycle exit and altered gene expression and cell morphology. In humans it is considered a tumor suppressor mechanism, mediating removal of damaged or mutated cells from

A role for polyploidy in the tumorigenicity of Pim-1-expressing human prostate and mammary epithelial cells.

Meejeon Roh et al.

PloS one, 3(7), e2572-e2572 (2008-07-04)

Polyploidy is a prominent feature of many human cancers, and it has long been hypothesized that polyploidy may contribute to tumorigenesis by promoting genomic instability. In this study, we investigated whether polyploidy per se induced by a relevant oncogene can

Comparison of 60 or 90 mg/m(2) of daunorubicin in induction therapy for acute myeloid leukemia with intermediate or unfavorable cytogenetics.

Raynier Devillier et al.

American journal of hematology, 90(2), E29-E30 (2014-11-05)

Acute myeloid leukemia in first remission: to choose transplantation or not?

Richard M Stone

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(10), 1262-1266 (2013-02-27)

A 42-year-old woman presented with bruising and fatigue. Her WBC count was 10,370/μL, with a differential showing 5% polys, 5% monos, 10% lymphocytes, and 80% myeloid-appearing blasts, some of which contained Auer rods (Fig 1). Bone marrow examination revealed 90%

Mutant DNMT3A clone evading chemotherapy and infiltrating central nervous system in a patient with molecularly good-risk acute myeloid leukemia.

Yi-Yang Chen et al.

Annals of hematology, 93(8), 1441-1442 (2013-12-18)

Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004.

Ursula Creutzig et al.

Blood, 122(1), 37-43 (2013-05-25)

Outcomes of patients with acute myeloid leukemia (AML) improve significantly by intensification of induction. To further intensify anthracycline dosage without increasing cardiotoxicity, we compared potentially less cardiotoxic liposomal daunorubicin (L-DNR) to idarubicin at a higher-than-equivalent dose (80 vs 12 mg/m(2)

Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL).

Michael E Rytting et al.

Cancer, 120(23), 3660-3668 (2014-07-22)

Various trials have reported improved outcomes for adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) who received treatment with pediatric-based regimens. Those reports prompted the current investigation of the pediatric augmented Berlin-Frankfurt-Münster (ABFM) regimen in AYA patients. The

Adipose tissue attracts and protects acute lymphoblastic leukemia cells from chemotherapy.

Rocky Pramanik et al.

Leukemia research, 37(5), 503-509 (2013-01-22)

Obesity is associated with an increased risk of acute lymphoblastic leukemia (ALL) relapse. Using mouse and cell co-culture models, we investigated whether adipose tissue attracts ALL to a protective microenvironment. Syngeneically implanted ALL cells migrated into adipose tissue within ten

1/3